ALK-positive anaplastic large cell lymphoma (ALCL ALK+) is an extremely rare aggressive T-cell lymphoma that exhibits a chromosomal translocation involving the ALK gene. It accounts for 0.5% of adult lymphomas. We present a case of a 36-year-old female patient admitted to the hospital in poor overall condition with hyperleukocytosis, lymphadenopathy, organomegaly, tachycardia, dyspnea, and overall weakness, diagnosed with ALK-positive ALCL. In the first line of treatment, a standard CHO(E)P (cyclophosphamide, doxorubicin, vincristine, (etoposide), prednisone) chemotherapy was given. In second-line therapy, combining brentuximab vedotin (BV) with conventional chemotherapy resulted in the achievement of complete remission (CR). This paper aims to highlight the challenges in making a definitive diagnosis of ALCL, to emphasize the importance of cytogenetic techniques, and to discuss current treatment options from the literature review.
No takes yet. Share an insight, caveat, or question.
Brzezińska et al. (2024) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: